# ATOGEN

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/atogen

- Industry: Biotechnology
- Headquarters: South Korea
- Website: www.atogen.kr
- Total disclosed funding: $5.2M
- Latest round: Series A (Jan 15, 2020)
- Investors on record: 5

## About

Based in South Korea and founded in 2012, ATOGEN formerly known as Unitech Science Co., Ltd. operates as a biotechnology company that focuses on the development of new drugs and food materials to improve health. In September 2022, ATOGEN raised KRW 10 billion in venture funding from Yuhan Corporation which holds a 60% majority stake in the company.

ATOGEN provides functional probiotics products such as HAC01 analyses the body fat loss and blood glucose reduction activities, ATG-K2 analyses the effect of body fat and fatty liver, ATG-K8, ATG-F4 enhance muscle function and dopamine secretion, ATG-F5 improve wrinkle formation, acne, whitening, etc.

The company plans to use the September 2022 funding to develop microbiome-based therapeutics and expand its functional probiotic business.

## Funding rounds

- Series A, Jan 15, 2020, $5.2M — SBI Investment Korea, Brain Asset Management, KB Securities, T Investment, KClavis Investment

## Investors

- SBI Investment Korea (https://capitalatlas.ai/funds/sbi-investment-korea) — Series A
- Brain Asset Management (https://capitalatlas.ai/funds/brain-asset-management) — Series A
- KB Securities (https://capitalatlas.ai/funds/kb-securities) — Series A
- T Investment (https://capitalatlas.ai/funds/t-investment) — Series A
- KClavis Investment (https://capitalatlas.ai/funds/kclavis-investment) — Series A